SCHEMBL4846419

SCHEMBL4846419

CC(C)(C)OC(=O)N1CCC(c2ccc(F)c(Cl)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
CNR1 P21554 2/20 0.51
GPR35 Q9HC97 1/20 0.51
GPR55 Q9Y2T6 1/20 0.51
NAMPT P43490 1/20 0.51
STS P08842 4/20 0.50
KDM4E B2RXH2 1/20 0.50
THRB P10828 1/20 0.50
PDE4B Q07343 1/20 0.49
DPP4 P27487 1/20 0.49
HRH3 Q9Y5N1 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
USP2 O75604 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
USP30 Q70CQ3 1/20 0.47
IDO1 P14902 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342575 0.90 TACR3 (0.51) MAPTNAMPTSTSKDM4ETHRB
SCHEMBL4886160 0.90 TACR3 (0.51) MAPTNAMPTSTSKDM4ETHRB
SCHEMBL4735264 0.89 NAMPT (0.54) MAPTNPSR1NAMPTSTSKDM4E
SCHEMBL19702757 0.89 DPP4 (0.55) MAPTNAMPTKDM4ETHRBPDE4B
SCHEMBL24309415 0.86 NAMPT (0.52) MAPTNAMPTKDM4ETHRBPDE4B
SCHEMBL29567337 0.86 NAMPT (0.52) MAPTNAMPTKDM4ETHRBPDE4B
SCHEMBL19103523 0.86 NAMPT (0.52) MAPTNPSR1NAMPTSTSKDM4E
SCHEMBL15862956 0.85 NAMPT (0.51) MAPTNPSR1NAMPTSTSKDM4E
SCHEMBL3988015 0.85 DPP4 (0.52) MAPTNAMPTKDM4ETHRBPDE4B
SCHEMBL8310737 0.84 NAMPT (0.60) MAPTNPSR1CNR1NAMPTSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS PFIZER INC. 2008-12-18 US disclosed
WO-2008012623-A1 BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR PFIZER PRODUCTS INC. (US) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS AZI2, PAICS, UGT2B7 MAPT 3948/4885NPSR1 2701/4885CNR1 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.